GAS is an important human pathogen responsible for a number of significant infections but is most commonly associated with pharyngitis. ARF is an autoimmune sequela of streptococcal pharyngitis, when ...

‌Chorea is a movement disorder that stems from something wrong with the basal ganglia nerve structure deep in your brain. It causes involuntary movements of the hands, feet, and face. These movements ...

Dyskinesia is a state in which someone experiences involuntary movements. Chorea is a type of dyskinesia. Other types of dyskinesia include tics, myoclonus, dystonia, and akathisia. There are ...

Chorea is characterized by the occurrence of unwilled, irregular movements, abrupt and aimless, in one or more limbs or in the face and trunk, which unlike the movements of tics or habit spasms, ...

Chorea and hemiballismus are both forms of involuntary movement disorders. Hemiballismus can cause sudden, violent, and flinging motions. Chorea can cause irregular, spontaneous, and nonrepetitive ...

An alternate, unitary explanation of these findings was suggested by a previous study from this hospital. 7 Data were presented showing that when chorea, rheumatic polyarthritis and carditis occur in ...

NEW YORK, Aug. 15 /PRNewswire/ -- The Hereditary Disease Foundation (HDF) is extremely pleased the U.S. Food and Drug Administration has approved Xenazine, or tetrabenazine, for the treatment of ...

Chorea can be caused in several other conditions as well such as Sydenham’s chorea (a complication of rheumatic fever), drugs (levodopa, anti-convulsants, and anti-psychotics), metabolic and endocrine ...

Background A 75-year-old woman with rheumatoid arthritis presented with a 4-year history of chorea to a hospital movement disorder clinic. The involuntary movements were initially mild, affecting only ...

Neurocrine Biosciences is a pharmaceutical company specializing in the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. The company recently submitted a proposal for the use ...

SAN DIEGO, Aug. 18, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration (FDA) has approved INGREZZA® (valbenazine) capsules for the ...